Firm
Transactions specialists at Paul Weiss are advising on the high-profile split of Kraft Heinz into two companies, while Skadden is also involved in the deal
Youngmin Park joins us for our ‘Five minutes with’ series to discuss learning languages, moonlighting as a drummer, and why late is better than never
The record-breaking $1.5 billion settlement between the AI company and book authors may not lead to rapid resolution of other cases, say copyright lawyers
Leaders at two Brazilian law firms outline strategies to adjust to trademark fee changes at Brazil's IP office while urging clients to apply before September 20
Sponsored
Sponsored
-
Sponsored by Saint Island International Patent & Law OfficesChiu-ling Lin of Saint Island International Patent & Law Offices discusses a ruling by the Supreme Administrative Court in Taiwan that highlights the importance of claim definiteness and enabling requirements in crystalline form patent cases -
Sponsored by Tilleke & GibbinsAfter decades of debate, Vietnam has recognised the need to create a court dedicated to intellectual property matters, says Loc Xuan Le of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins
-
Sponsored by Gün and PartnersSelin Sinem Erciyas and Zeynep Çağla Üstün explore whether Turkey, as a non-EU state party to the European Patent Convention, might still face the Unified Patent Court’s jurisdiction under EU regulations
-
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Yifan Lu of Tahota Law Firm explore Beijing's pioneering role among eight Chinese provinces and municipalities designated to work on the development of the country’s data intellectual property rights framework
-
Sponsored by Spoor & FisherNew patent and utility model procedures and updated fees form part of a legislative update to the Bangui Agreement that became effective in the new year, explains Craig Kahn of Spoor & Fisher Jersey
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer and Gisela Grabow of Maiwald explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster competition and enhance patient access
